Loading.
Preparing your Shotlee experience
Preparing your Shotlee experience

The weight loss drug Ozempic has been introduced in India by Novo Nordisk, with a weekly cost of $24.35 for 0.25mg doses. This move occurs amidst increasing global demand for weight management solutions. India represents a significant market due to its high rates of type 2 diabetes and obesity.
The weight loss medication Ozempic was released in India on Friday. The 0.25mg doses are priced at $24.35 per week.
Pharmaceutical company Novo Nordisk initiated this action as demand for weight loss therapies increases globally. The company stated that Ozempic will be available in injectable pens, with dosages of 0.25mg, 0.5mg, and 1mg. Health tracking apps like Shotlee can help monitor progress for individuals using such medications.
Monthly costs in India have been established at 8,800 rupees ($97) for a 0.25mg dose. The 0.5mg dose will cost 10,170 rupees, while the 1mg dose is priced at 11,175 rupees per month. Each pen provides four weekly doses.
Ozempic, which gained approval from the US Food and Drug Administration in 2017 for treating Type 2 diabetes, has become increasingly popular. Its widespread use for weight loss is attributed to its appetite-suppressing qualities. Novo also noted its beneficial effects for individuals with cardiovascular and kidney problems.
According to Vikrant Shrotriya, corporate vice president and managing director of Novo Nordisk India, "Ozempic also supports weight loss of up to 8kg in diabetic patients... therefore, this drug offers advantages beyond just controlling blood sugar levels."
India has the second-largest population of individuals with Type 2 diabetes, following China. It also experiences rising obesity rates. This makes the country a crucial area for pharmaceutical firms competing for a portion of the rapidly expanding weight loss treatment market. Analysts project the sector will reach a valuation of $150 billion annually by the decade's end.
Novo launched Ozempic in India this month to establish a market presence before local companies introduce cheaper alternatives. Patents for semaglutide, the medication sold under the Ozempic and Wegovy brands, are set to expire in March 2026.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from The National
View Original Article
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.

A recent study indicates a possible connection between GLP-1 drugs and a reduced risk of epilepsy in individuals with type 2 diabetes. The research, published in Neurology, provides preliminary evidence of neurological advantages from these medications. Larger trials are necessary to confirm these findings.

Recent research highlights a growing trend of British men turning to weight loss injections. Data indicates a significant shift in usage, with men increasingly adopting these treatments.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨